2444 related articles for article (PubMed ID: 28673901)
41. Potential Cardiovascular Disease Events Prevented with Adoption of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline.
Bress AP; Colantonio LD; Cooper RS; Kramer H; Booth JN; Odden MC; Bibbins-Domingo K; Shimbo D; Whelton PK; Levitan EB; Howard G; Bellows BK; Kleindorfer D; Safford MM; Muntner P; Moran AE
Circulation; 2019 Jan; 139(1):24-36. PubMed ID: 30586736
[TBL] [Abstract][Full Text] [Related]
42. Retrospective Evaluation of ASCVD Risk and Statin Therapy Need in Nondiabetic Patients Based on the 2013 ACC/AHA Cholesterol Guidelines.
Koenigsfeld C; Sayler M; Smith HL; Meyer K; Lehman N; Logemann C; Bottenberg M; Bryant G; Obermark M
J Pharm Pract; 2017 Jun; 30(3):300-305. PubMed ID: 27026635
[TBL] [Abstract][Full Text] [Related]
43. Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease based on available randomised clinical trial evidence: The Rotterdam Study.
Pavlović J; Greenland P; Deckers JW; Kavousi M; Hofman A; Ikram MA; Franco OH; Leening MJ
Eur J Prev Cardiol; 2018 Mar; 25(4):420-431. PubMed ID: 29171772
[TBL] [Abstract][Full Text] [Related]
44. Implications of the new American College of Cardiology/American Heart Association cholesterol guidelines for primary atherosclerotic cardiovascular disease event prevention in a multi ethnic cohort: Multi-Ethnic Study of Atherosclerosis (MESA).
Yeboah J; Sillau S; Delaney JC; Blaha MJ; Michos ED; Young R; Qureshi WT; McClelland R; Burke GL; Psaty BM; Herrington DM
Am Heart J; 2015 Mar; 169(3):387-395.e3. PubMed ID: 25728729
[TBL] [Abstract][Full Text] [Related]
45. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E
Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708
[TBL] [Abstract][Full Text] [Related]
46. Adherence to lipid management guidelines is associated with lower mortality and major adverse limb events in patients undergoing revascularization for chronic limb-threatening ischemia.
O'Donnell TFX; Deery SE; Darling JD; Shean KE; Mittleman MA; Yee GN; Dernbach MR; Schermerhorn ML
J Vasc Surg; 2017 Aug; 66(2):572-578. PubMed ID: 28506476
[TBL] [Abstract][Full Text] [Related]
47. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
deGoma EM; Ahmad ZS; O'Brien EC; Kindt I; Shrader P; Newman CB; Pokharel Y; Baum SJ; Hemphill LC; Hudgins LC; Ahmed CD; Gidding SS; Duffy D; Neal W; Wilemon K; Roe MT; Rader DJ; Ballantyne CM; Linton MF; Duell PB; Shapiro MD; Moriarty PM; Knowles JW
Circ Cardiovasc Genet; 2016 Jun; 9(3):240-9. PubMed ID: 27013694
[TBL] [Abstract][Full Text] [Related]
48. Statin eligibility and cardiovascular risk burden assessed by coronary artery calcium score: comparing the two guidelines in a large Korean cohort.
Rhee EJ; Park SE; Oh HG; Park CY; Oh KW; Park SW; Blankstein R; Plutzky J; Lee WY
Atherosclerosis; 2015 May; 240(1):242-9. PubMed ID: 25818250
[TBL] [Abstract][Full Text] [Related]
49. Comparison of Adherence to the 2013 ACC/AHA Cholesterol Guideline in a Teaching Versus Nonteaching Outpatient Clinic.
Cheng-Lai A; Snead J; Ng C; Verges C; Chung P
Ann Pharmacother; 2018 Apr; 52(4):338-344. PubMed ID: 29103310
[TBL] [Abstract][Full Text] [Related]
50. Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.
Yeboah J; Polonsky TS; Young R; McClelland RL; Delaney JC; Dawood F; Blaha MJ; Miedema MD; Sibley CT; Carr JJ; Burke GL; Goff DC; Psaty BM; Greenland P; Herrington DM
Circulation; 2015 Sep; 132(10):916-22. PubMed ID: 26224808
[TBL] [Abstract][Full Text] [Related]
51. Race-Sex Differences in Statin Use and Low-Density Lipoprotein Cholesterol Control Among People With Diabetes Mellitus in the Reasons for Geographic and Racial Differences in Stroke Study.
Gamboa CM; Colantonio LD; Brown TM; Carson AP; Safford MM
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28490523
[TBL] [Abstract][Full Text] [Related]
52. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012.
Wong ND; Young D; Zhao Y; Nguyen H; Caballes J; Khan I; Sanchez RJ
J Clin Lipidol; 2016; 10(5):1109-18. PubMed ID: 27678427
[TBL] [Abstract][Full Text] [Related]
53. Cardiovascular Risk and Statin Eligibility in Primary Prevention: A Comparison between the Brazilian and the AHA/ACC Guidelines.
Cesena FHY; Valente VA; Santos RD; Bittencourt MS
Arq Bras Cardiol; 2020 Sep; 115(3):440-449. PubMed ID: 33027365
[TBL] [Abstract][Full Text] [Related]
54. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) guidelines for management of dyslipidemia and cardiovascular disease risk reduction: Putting evidence in context.
Al Rifai M; Blumenthal RS; Stone NJ; Schofield RS; Orringer CE; Michos ED; Heidenreich PA; Braun L; Birtcher KK; Smith SC; Nambi V; Grundy S; Virani SS
Prog Cardiovasc Dis; 2021; 68():2-6. PubMed ID: 34371083
[TBL] [Abstract][Full Text] [Related]
55. Comparison of ACC/AHA and ESC Guideline Recommendations Following Trial Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: Results From the Population-Based Rotterdam Study.
Pavlovic J; Greenland P; Deckers JW; Brugts JJ; Kavousi M; Dhana K; Ikram MA; Hofman A; Stricker BH; Franco OH; Leening MJ
JAMA Cardiol; 2016 Sep; 1(6):708-13. PubMed ID: 27439175
[TBL] [Abstract][Full Text] [Related]
56. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
[TBL] [Abstract][Full Text] [Related]
57. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort.
Kavousi M; Leening MJ; Nanchen D; Greenland P; Graham IM; Steyerberg EW; Ikram MA; Stricker BH; Hofman A; Franco OH
JAMA; 2014 Apr; 311(14):1416-23. PubMed ID: 24681960
[TBL] [Abstract][Full Text] [Related]
58. Guideline concordance of new statin prescriptions: who got a statin?
Cascino T; Vali M; Redberg R; Bravata DM; Boscardin J; Eilkhani E; Keyhani S
Am J Manag Care; 2017 Sep; 23(9):528-533. PubMed ID: 29087155
[TBL] [Abstract][Full Text] [Related]
59. Clinical pharmacist understanding of the 2013 American College of Cardiology/American Heart Association cholesterol guideline.
Bucheit JD; Helsing H; Nadpara P; Virani SS; Dixon DL
J Clin Lipidol; 2018; 12(2):367-374.e3. PubMed ID: 29277495
[TBL] [Abstract][Full Text] [Related]
60. Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry.
Xian Y; Navar AM; Li S; Li Z; Robinson J; Virani SS; Louie MJ; Koren A; Goldberg A; Roger VL; Wilson PWF; Peterson ED; Wang TY
J Am Heart Assoc; 2019 Oct; 8(19):e013229. PubMed ID: 31554462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
